(R)-carnitine/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
(R)-carnitine — no detected effect on hospital length of stay
Evidence strength: moderate.FindingNull result“Differences in fatigue (moderate/severe, >4 on BFI), present in 28,6% of L-Carnitine patients versus 41,7% in the placebogroup,were not statistically significant, nor was the survival benefit (median 519 ± 50d versus 399 ± 43d with placebo), and the reduction in length of hospital stay (36 ± 4d versus 41 ± 9d with placebo).”
Quoted verbatim from L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 4 g/day oral liquid L-carnitine
- Population
- Patients with advanced irresectable pancreatic adenocarcinoma (UICC stage IV), most receiving chemotherapy
L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.2012PMID:2282416810.1186/1475-2891-11-52Permalink
To cite this finding: https://catalystproject.ai/e/01M5SA24332RXFPK7AS7Y0DXDF